UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2444-2447

2006

Link zum Volltext

Verfügbarkeit prüfen

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Therapeutic Advances in Medical Oncology, 2012-05, Vol.4 (3), p.127-137

Lønning, Per E.

2012

Link zum Volltext

Verfügbarkeit prüfen

Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594

Lab on a chip, 2017-09, Vol.17 (18), p.3186-3187

Lønning, Per E

2017

Link zum Volltext

Verfügbarkeit prüfen

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

Translational oncology, 2017-10, Vol.10 (5), p.806-817

2017

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of the CHEK2 R95 germline mutation

Hereditary cancer in clinical practice, 2016-09, Vol.14 (1), p.19-19, Article 19

2016

Link zum Volltext

Verfügbarkeit prüfen

Genomsekvensering for persontilpasset kreftbehandling

Tidsskrift for den Norske Lægeforening, 2012, Vol.132 (21), p.2406-2408

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT010: Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT010-CT010

2017

Link zum Volltext

Verfügbarkeit prüfen

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

JNCI : Journal of the National Cancer Institute, 2004-06, Vol.96 (11), p.884-884

2004

Link zum Volltext

Verfügbarkeit prüfen

MDM2 Promoter SNP344TA (rs1196333) Status Does Not Affect Cancer Risk

PloS one, 2012-04, Vol.7 (4), p.e36263

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3704: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension in a single-arm Phase II study

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3704-3704

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1092: Alterations of the retinoblastoma gene in stage III breast cancers

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.1092-1092

2010

Link zum Volltext

Verfügbarkeit prüfen

A Mitochondrial Target Sequence Polymorphism in MnSOD Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide

Clinical cancer research, 2009-06, Vol.15 (12), p.4165-4173

2009

Link zum Volltext

Verfügbarkeit prüfen

Genome sequencing for personalized cancer treatment

Tidsskrift for den Norske Lægeforening, 2012-11, Vol.132 (21), p.2406-2408

2012

Link zum Volltext

Verfügbarkeit prüfen

Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer

Breast cancer online, 2006-01, Vol.9 (1), p.1-3, Article e3

Lønning, P. E.

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1792: MDM2 promoter variants and mRNA expression in irradiated lymphocytes

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1792-1792

2013

Link zum Volltext

Verfügbarkeit prüfen

Exemestane in Breast Cancer: Current Status and Future Directions

Clinical breast cancer, 2000-09, Vol.1, p.S28-S33

Lønning, Per E.

2000

Link zum Volltext

Verfügbarkeit prüfen

Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer

The journal of clinical endocrinology and metabolism, 1996-06, Vol.81 (6), p.2216-2221

1996

Link zum Volltext

Verfügbarkeit prüfen

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

JNCI : Journal of the National Cancer Institute, 2004-06, Vol.96 (11), p.883-883

2004

Link zum Volltext

Verfügbarkeit prüfen

Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters

Molecular cancer, 2006-10, Vol.5, p.47-47

2006

Link zum Volltext

Verfügbarkeit prüfen

Foreword

Acta oncologica, 1996-01, Vol.35 (sup5), p.3-4

1996

Link zum Volltext

Verfügbarkeit prüfen

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-I in post-menopausal breast cancer patients

Clinical endocrinology (Oxford), 1995-01, Vol.42 (1), p.23-30

1995

Link zum Volltext

Verfügbarkeit prüfen

Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility

Oncogenomics, 2004, p.77-100

2004

Link zum Volltext

Verfügbarkeit prüfen

MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells

Translational oncology, 2019-01, Vol.12 (1), p.170-179

2019

Link zum Volltext

Verfügbarkeit prüfen

Golgi-localized PAQR4 mediates Anti-apoptotic Ceramidase Activity in Breast Cancer

Cancer research (Chicago, Ill.), 2020-04

2020

Link zum Volltext

Verfügbarkeit prüfen

rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk

Scientific reports, 2016-11, Vol.6 (1), p.36874, Article 36874

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(30)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

Prevalence of the CHEK2 R95 germline mutation

Genomsekvensering for persontilpasset kreftbehandling

Abstract CT010: Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

MDM2 Promoter SNP344TA (rs1196333) Status Does Not Affect Cancer Risk

Abstract 3704: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension in a single-arm Phase II study

Abstract 1092: Alterations of the retinoblastoma gene in stage III breast cancers

A Mitochondrial Target Sequence Polymorphism in MnSOD Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide

Genome sequencing for personalized cancer treatment

Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer

Abstract 1792: MDM2 promoter variants and mRNA expression in irradiated lymphocytes

Exemestane in Breast Cancer: Current Status and Future Directions

Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters

Foreword

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-I in post-menopausal breast cancer patients

Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility

MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells

Golgi-localized PAQR4 mediates Anti-apoptotic Ceramidase Activity in Breast Cancer

rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk

Aktive Filter

Suchergebnisse filtern